ImmuCell Corporation (ICCC)
- Previous Close
5.30 - Open
5.36 - Bid --
- Ask --
- Day's Range
5.21 - 5.45 - 52 Week Range
3.34 - 5.82 - Volume
32,156 - Avg. Volume
21,025 - Market Cap (intraday)
47.401M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.26 - Earnings Date Aug 11, 2025 - Aug 15, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments: Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, the company developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
immucell.comRecent News: ICCC
View MorePerformance Overview: ICCC
Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ICCC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ICCC
View MoreValuation Measures
Market Cap
47.40M
Enterprise Value
58.74M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.62
Price/Book (mrq)
1.72
Enterprise Value/Revenue
2.22
Enterprise Value/EBITDA
55.07
Financial Highlights
Profitability and Income Statement
Profit Margin
-0.99%
Return on Assets (ttm)
0.26%
Return on Equity (ttm)
-1.01%
Revenue (ttm)
27.3M
Net Income Avi to Common (ttm)
-271.78k
Diluted EPS (ttm)
-0.26
Balance Sheet and Cash Flow
Total Cash (mrq)
4.6M
Total Debt/Equity (mrq)
50.56%
Levered Free Cash Flow (ttm)
992.86k